# Selank Research: Mechanism, Key Studies & the Evidence Base > Selank research in depth: GABA positive allosteric modulation, enkephalinase inhibition, BDNF, monoamine and immune effects, plus the key rodent and Russian clinical studies. Cited throughout. GABA modulation, enkephalinase inhibition, BDNF, and immune signaling — the studies behind each, with every quantitative claim cited. ## Before the details Here is the **Selank research** without the jargon. Selank is a lab-made peptide built to be a steadier version of a natural immune peptide called tuftsin. Scientists think it calms anxiety through four routes at once, which is unusual. First, it gently turns up the brain's main calming system (GABA) without flipping it on hard like older drugs. Second, it slows the enzymes that destroy the body's own feel-good peptides (enkephalins), so they last longer. Third, it raises a growth protein (BDNF) tied to learning and a flexible brain. Fourth, because of its immune-peptide origins, it nudges the immune system's signaling. Most of the proof comes from rats and from small human studies done in Russia, which is both genuinely encouraging and a real limit — the findings are promising but not yet confirmed widely. Every claim below points to a study you can check. ## Selank peptide The Selank peptide is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro (molecular formula C33H57N11O9, molecular weight ~751.9 Da, CAS 129954-34-3). It is the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg, cut from the heavy chain of immunoglobulin G) extended at the C-terminus with Pro-Gly-Pro. That tail is the whole design point: it dramatically slows the enzymatic degradation that limits native tuftsin, giving the molecule the metabolic stability needed to act in the brain. The peptide is supplied lyophilized for research and reconstituted solutions are kept refrigerated. Its lineage from an immune peptide is also why its biology runs in two channels at once — neurological and immunological — a profile that sets it apart from conventional small-molecule anxiolytics. ## GABA modulation — the core anxiolytic mechanism Selank's anxiolytic activity centers on the GABA system, the brain's principal inhibitory (calming) network. A mechanistic review establishes that Selank acts as a positive allosteric modulator of [3H]GABA binding — it binds at a site distinct from where GABA itself docks and enhances the receptor's response — with subtype-selective, concentration-dependent modulation, and it can block the modulatory activity of diazepam and olanzapine, indicating distinct but overlapping binding sites [1]. The effect reaches the level of gene expression. A single 300 µg/kg dose of Selank in rats changed the expression of 45 genes involved in GABAergic neurotransmission at one hour and 22 genes at three hours, and the direction of those shifts correlated positively with the changes produced by GABA itself [4]. Functionally, in an unpredictable chronic mild stress model the combination of diazepam with Selank was the most effective intervention for reducing anxiety, with combined treatment restoring behavior toward pre-stress levels — direct behavioral evidence of a GABAergic interaction [7]. ## Enkephalinase inhibition — the second, non-GABA route Selank's second mechanism runs through the body's own opioid peptides. In human plasma in vitro, Selank dose-dependently inhibited the enzymatic hydrolysis of enkephalins — endogenous opioid peptides involved in pain and stress regulation — with an IC50 around 15 µM [2]. By slowing the enzymes (enkephalinases) that break enkephalins down, Selank is proposed to normalize the shortened enkephalin half-life observed in generalized anxiety, stabilizing an anti-anxiety system the body already runs. This enkephalinase-inhibition pathway is part of why Selank's anxiolytic profile differs from benzodiazepines, which act purely on GABA receptors. ## BDNF, memory, and the nootropic findings Beyond calm, Selank shows a learning-and-memory side. Intranasal administration regulated (increased) BDNF expression in the rat hippocampus in vivo — BDNF is a neurotrophin that supports neuron survival and plasticity — linking the peptide to neurotrophic signaling and offering a mechanism for its nootropic effects [3]. The behavioral data follow. Selank had an optimizing action on a conditioned active-avoidance reflex in rats, a standard learning paradigm [8], and experimentally improved learning and memory processes [9]. In neurotoxin (MPTP) models of memory impairment it showed a compensatory, protective effect on disturbed mnestic function [10][11], and it was used to correct measures of integrative brain activity and biogenic amine levels [12]. The monoaminergic thread is direct: Selank altered the content of serotonin, dopamine, and their metabolites in mouse brain in a strain-dependent manner [18]. ## The immune dimension and broader physiology Because it descends from tuftsin, Selank carries genuine immunomodulatory activity. In patients with anxiety-asthenic disorders it shifted the Th1/Th2 cytokine balance and modulated peripheral-blood IL-6 expression, leading the authors to characterize it as a novel immunomodulator alongside its anxiolytic action [5]. It influenced cytokine levels under stress conditions in rats [19] and showed antiviral activity in experimental influenza infection in mice, consistent with tuftsin-derived immune activity [20]. Its physiology extends further still: Selank affected gastric wall blood flow and supported gastric mucosal protection in rats [13], and it and its metabolites maintained homeostasis in the gastric mucosa [14]. It also altered stress-induced changes in colon microbiota composition [15] and modulated hepatocyte functional indices under immobilization stress [17] — a breadth that reflects its multi-system, peptide-based biology. ## Interpreting the evidence base The Selank literature is consistent and mechanistically coherent — and it carries a clear limitation that good interpretation must state plainly. The great majority of studies originate from a small set of Russian research groups, notably the Institute of Molecular Genetics RAS and the Zakusov Institute of Pharmacology, and many key papers appear in Russian-language journals with English abstracts only, limiting full methodological scrutiny. Independent Western replication is limited; human evidence is far thinner than for approved anxiolytics; and the pharmacokinetics of intact Selank in humans are poorly characterized in mainstream literature. Selank is not approved by the FDA or EMA. None of that erases the findings — it frames them. The right reading is a promising, reproducible-within-its-source research program awaiting wider, independent confirmation. --- A hopeful read of the Selank research, told honestly — editorial summaries of the published science, never medical advice.